Soluble Epoxide Hydrolase in Inflammatory and Immune Diseases: A Bibliometric and Visualization Analysis in 2000-2025

Soluble epoxide hydrolase (sEH) is extensively involved in the pathophysiological processes of inflammatory and immune diseases. This study aims to systematically analyze the current research status, cooperation networks, and evolutionary trends in this field using bibliometric methods to provide a reference for future basic research and clinical translation.

Articles and reviews related to sEH, inflammation, and immunity published from January 1, 2000, to December 31, 2025, were retrieved from the Web of Science (WoS) and Scopus databases. VOSviewer, CiteSpace, and the bibliometrix package in R were utilized to perform visualization analysis of publication volume, distribution of countries and institutions, core authors, highly cited publications, and keywords.

A total of 2240 publications were included in this study. The annual publication volume exhibited a steady upward trend, reaching a periodic peak in 2021. The United States ranked first globally in publication volume (908 publications). The University of California was the most contributing institution, and its scholar, Bruce Hammock, held a core position in both publication volume and academic impact. PNAS was the most cited journal in this field. Current research frontiers focus on pharmacodynamics, molecular docking, protein mechanisms, lipid chromatography mass spectrometry, and clinical translation studies.

This study presents the first systematic knowledge map of sEH in inflammatory and immune diseases. sEH inhibitors have emerged as highly promising targets for anti-inflammatory and immunomodulatory therapy. Clinical translation will be the key development direction for this field in the future.